Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 14/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321969 | 0.88 | KIT (0.87) | KITMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17782822 | 0.87 | KIT (0.81) | KIT | |
| SCHEMBL16365881 | 0.84 | KIT (0.66) | KITMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16365889 | 0.80 | KIT (1.00) | KITMEN1KMT2ANPC1RAB9A | |
| SCHEMBL207443 | 0.80 | MEN1 (0.70) | KITMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17782833 | 0.79 | KIT (0.94) | KIT | |
| SCHEMBL17782775 | 0.79 | KIT (0.79) | KIT | |
| SCHEMBL11903463 | 0.77 | KDM4E (0.61) | KITMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17782830 | 0.77 | KIT (0.91) | KITMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17782856 | 0.76 | KIT (0.85) | KITMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | claimed |
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | claimed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3010906-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB Science (FR) | 2016-04-27 | — | — | EP | claimed |
| WO-2014202763-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2014-12-24 | — | — | WO | claimed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | disclosed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | disclosed |
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | disclosed |
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2014202763-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | KIT, CHUK, CSNK1E | KIT 1/4885MEN1 3086/4885KMT2A 699/4885 |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | KIT, CHUK, CSNK1E | KIT 1/4885MEN1 3086/4885KMT2A 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.